Article | June 2, 2022

Outsourcing Highly Potent API – It's Both What You Know And Who You Know

Source: ISR Reports
doctor analyzes monoclonal antibodies GettyImages-1317916302

Advances in clinical pharmacology and oncology research have increased the demand for highly potent active pharmaceutical ingredients (HPAPI). New therapies, such as antibody-drug conjugates (ADCs), can better target cancerous tumors with less collateral damage to healthy cells while APIs used in medicines that treat other disease areas are becoming more potent and targeted. This is unquestionably good news for patients, many of whom can expect to suffer fewer side effects from the medications of the future. However, there is a challenge for drug makers who may want to begin producing higher potency APIs but have built their manufacturing systems around broad-spectrum medications that don’t use HPAPI or require high-containment facilities.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: